Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers
Plozasiran at 25 and 50 mg was well tolerated with acceptable safety profile in Chinese HVs. Safety, PK and PD profiles observed in the present study were consistent with the data reported from clinical studies conducted outside China.
Authors
- Lihang Qi
- Jack Shi
- Dong You
- Ye Li (ORCID: https://orcid.org/0000-0001-6338-7474)
- Haiyan Li (ORCID: https://orcid.org/0000-0002-8286-2813)
- Fangfang Wang (ORCID: https://orcid.org/0000-0002-5441-4490)
- Xiaoye Niu
Institutions
- Peking University (CN)
- Arrowhead Pharmaceuticals (United States) (US)
- Peking University Third Hospital (CN)
- Io Therapeutics (United States) (US)
- Beijing Haidian Hospital (CN)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1186/s12933-025-02929-9
- Citations
- 2
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Peking University
- Peking University Third Hospital